+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study



Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study



European Journal of Clinical Pharmacology 40(5): 473-476



The effects of ursodeoxycholic acid (UDCA, 450 mg daily) in patients with histologically proven chronic active hepatitis (CAH) have been evaluated in a randomized, double-blind, placebo-controlled study. Twenty-six patients with serum alanine aminotransferase (ALT) values at least twice the normal upper limit in two of three pre-treatment tests received UDCA or a placebo for twelve weeks. In all UDCA-treated patients, serum aspartate amino-transferase (AST), ALT, gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (AP) fell significantly after 4 weeks of treatment. There was a further decrease at the end of therapy, as well as a small but significant fall in total serum bilirubin. Conversely, 4 weeks after suspension of therapy, serum enzyme levels had increased, reaching values not much lower than those recorded before treatment. Total serum protein, albumin and gamma-globulin did not change after UDCA treatment. In the placebo group no significant variation in the test results were found. The results indicate that UDCA therapy in CAH, as has been observed in primary biliary cirrhosis and primary sclerosing cholangitis, is able to improve several indices of liver damage, without producing any toxic adverse effects.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039987117

Download citation: RISBibTeXText

PMID: 1679391


Related references

The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. Journal of Hepatology 20(3): 315-320, 1994

Effect of ursodeoxycholic acid udca on serum enzymes and liver histology in patients with chronic active hepatitis cah. Journal of Hepatology 13(SUPPL 2): S92, 1991

Ursodeoxycholic acid udca improves serum protein level in patients with chronic active hepatitis. Hepatology 12(4 PART 2): 998, 1990

Effect of ursodeoxycholic acid udca on liver function lf in patients with chronic active hepatitis and cirrhosis. European Journal of Clinical Investigation 20(2 PART 2): A62, 1990

Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double-blind controlled trial. Journal of International Medical Research 10(4): 278-282, 1982

Ursodeoxycholic acid udca in chronic hepatitis a double blind multicenter clinical trial. Gastroenterology 100(5 PART 2): 719, 1991

Ursodeoxycholic acid udca in chronic active hepatitis results of a controlled trial. Journal of Hepatology 13(SUPPL 2): S104, 1991

Ursodeoxycholic acid udca improves serum albumin levels in chronic active hepatitis. Gastroenterology 98(5 PART 2): A606, 1990

Effects of ursodeoxycholic acid in association with interferon-alpha-2a on sustained response in chronic hepatitis C A randomized double-blind placebo-controlled study. Gastroenterology 112(4 SUPPL ): A1239, 1997

One year ursodeoxycholic acid treatment of chronic viral hepatitis in heart transplanted patients Results of a prospective double-blind placebo randomized controlled study in 60 patients. Journal of Hepatology 25(SUPPL 1): 127, 1996

Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 13(2): 339-344, 1991

Double blind controlled trial of ursodeoxycholic acid udca versus placebo in the treatment of reflux gastritis in patients not submitted to gastric surgery. Acta Endoscopica 19(4): 251-257, 259-260, 1989

Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study. Transplantation 75(7): 977-982, 2003

Effects of different doses of ursodeoxycholic acid udca on liver function indices in patients with icteric primary biliary cirrhosis pbc. Gastroenterology 96(5 PART 2): A575, 1989

Effect of ursodeoxycholic acid udca treatment in patients with hypertransaminasemia a double blind clinical trial. Gastroenterology 94(5 PART 2): A524, 1988